MTOR and maternal uniparental disomy of chromosome 20: Two targeted therapies for the PI3K pathway are actively used with ET for HR+ metastatic breast cancers (MBCs); namely, the mammalian target of rapamycin (mTOR) inhibitor (everolimus) and a PI3Kα-specific inhibitor (alpelisib)18,19.